{
    "organizations": [],
    "uuid": "1f1d41b78c23c3d4233f95c30252f2bd92a81728",
    "author": "",
    "url": "https://www.reuters.com/article/brief-seattle-genetics-and-astellas-rece/brief-seattle-genetics-and-astellas-receive-fda-breakthrough-therapy-designation-for-enfortumab-vedotin-idUSASC09TL3",
    "ord_in_thread": 0,
    "title": "BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26, 2018 / 12:16 PM / Updated 5 minutes ago BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin Reuters Staff 1 Min Read March 26 (Reuters) - Seattle Genetics Inc: * SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER * SEATTLE GENETICS INC - COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA Source text for Eikon: Further company coverage:",
    "published": "2018-03-26T15:14:00.000+03:00",
    "crawled": "2018-03-26T15:26:29.043+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "genetics",
        "astellas",
        "receive",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "enfortumab",
        "vedotin",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "seattle",
        "genetics",
        "inc",
        "seattle",
        "genetics",
        "astellas",
        "receive",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "enfortumab",
        "vedotin",
        "locally",
        "advanced",
        "metastatic",
        "urothelial",
        "cancer",
        "seattle",
        "genetics",
        "inc",
        "co",
        "also",
        "evaluating",
        "enfortumab",
        "vedotin",
        "solid",
        "tumor",
        "including",
        "ovarian",
        "cell",
        "lung",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}